PRESS RELEASE published on 10/08/2024 at 07:45, 1 year 5 months ago Marinomed Biotech AG publishes remarkable results showing alleviation of allergic eye inflammation in patients treated with Tacrolimus eye drops in peer-reviewed journal Marinomed Biotech AG publishes study results on Tacrolimus eye drops, showing significant alleviation of allergic eye inflammation. Potential treatment for inflammatory eye diseases Marinomed Biotech AG Study Results Ocular Surface Tacrolimus Eye Drops Allergic Eye Inflammation
BRIEF published on 09/24/2024 at 07:50, 1 year 5 months ago Marinomed Biotech AG Reports Positive Clinical Results for Unique Carragelose Eye Drops Marinomed Biotech AG Carragelose Clinical Results Eye Drops Dry Eye Syndrome
BRIEF published on 09/24/2024 at 07:50, 1 year 5 months ago Marinomed Biotech AG annonce des résultats cliniques positifs pour ses gouttes oculaires uniques à base de carraghénane Marinomed Biotech AG Résultats Cliniques Carraghénose Gouttes Pour Les Yeux Syndrome De L'œil Sec
PRESS RELEASE published on 09/24/2024 at 07:45, 1 year 5 months ago Marinomed Biotech AG reports positive clinical results for unique Carragelose eye drops Marinomed Biotech AG reports positive clinical results for Carragelose eye drops, improving dry eye symptoms by 54%. The eye drops are well tolerated and hold valid Medical Device Directive certificate Marinomed Biotech AG Carragelose Clinical Results Dry Eye Eye Drops
BRIEF published on 09/18/2024 at 17:26, 1 year 6 months ago Marinomed Biotech AG Announces Capital Increase Excluding Subscription Rights Investors Capital Increase Marinomed Biotech AG Subscription Rights Issue Price
BRIEF published on 09/18/2024 at 17:26, 1 year 6 months ago Marinomed Biotech AG annonce une augmentation de capital hors droits de souscription Augmentation De Capital Investisseurs Marinomed Biotech AG Droits De Souscription Prix D'émission
PRESS RELEASE published on 09/18/2024 at 17:21, 1 year 6 months ago EQS-Adhoc: Marinomed Biotech AG resolves capital increase excluding statutory subscription rights by issuing 154,053 no-par value bearer shares at an issue price of EUR 5 per share Marinomed Biotech AG resolves capital increase by issuing 154,053 bearer shares at EUR 5 per share, excluding statutory subscription rights Capital Increase Marinomed Biotech AG Subscription Rights Bearer Shares EUR 5
BRIEF published on 09/15/2024 at 17:54, 1 year 6 months ago Marinomed Biotech AG Sets Price Range for Capital Increases Capital Increase Restructuring Share Price Investor Negotiations Marinomed Biotech
BRIEF published on 09/15/2024 at 17:54, 1 year 6 months ago Marinomed Biotech AG fixe une fourchette de prix pour ses augmentations de capital Augmentation De Capital Restructuration Cours De L'action Biotechnologie Marinomed Négociations Avec Les Investisseurs
PRESS RELEASE published on 09/15/2024 at 17:49, 1 year 6 months ago EQS-Adhoc: Marinomed Biotech AG sets price range for potential 10% capital increase and potential second capital increase, in each case excluding statutory subscription rights Marinomed Biotech AG sets price range for potential 10% capital increase and second capital increase, excluding statutory subscription rights Capital Increase Marinomed Biotech AG Price Range Authorized Capital 2024 Restructuring Proceedings
Published on 03/23/2026 at 22:40, 4 hours 15 minutes ago Troubadour Announces Withdrawal of Non-Brokered Private Placements
Published on 03/23/2026 at 22:30, 4 hours 25 minutes ago Gregory J. Leia Sells Shares in Waskahigan Oil & Gas Corp
Published on 03/23/2026 at 22:00, 4 hours 55 minutes ago Hillcrest Participates in APEC 2026 and Announces Shares for Debt Offering
Published on 03/23/2026 at 21:18, 5 hours 37 minutes ago Amdocs Announces Appointment of Shimie Hortig to the Board of Directors Upon Shuky Sheffer's Retirement as Director and Chief Executive Officer
Published on 03/24/2026 at 02:00, 55 minutes ago Discover a season of arts and sports mega events in Hong Kong
Published on 03/24/2026 at 00:55, 2 hours ago mymediset Introduces Agentic AI for MedTech Supply Chains at LogiMed 2026
Published on 03/24/2026 at 00:09, 2 hours 45 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Appendix 3C - change of buy back details
Published on 03/23/2026 at 22:05, 4 hours 50 minutes ago DeFi Technologies Provides Update on Timing of Annual Filings
Published on 03/23/2026 at 21:05, 5 hours 50 minutes ago Abivax annonce ses résultats financiers pour l’exercice 2025 et fait le point sur l’avancement de ses activités
Published on 03/23/2026 at 19:08, 7 hours 47 minutes ago Reporting on share buyback transactions carried out between March 16 and March 20, 2026
Published on 03/23/2026 at 19:08, 7 hours 47 minutes ago Déclaration de rachats d'actions effectués par la Compagnie de Saint-Gobain entre le 16 et le 20 mars 2026
Published on 03/23/2026 at 18:37, 8 hours 18 minutes ago ALTAREA : Déclaration d’opérations sur actions propres
Published on 03/23/2026 at 17:45, 9 hours 10 minutes ago ENGIE will build, own and operate its largest onshore wind farm worldwide in Egypt
Published on 03/23/2026 at 17:45, 9 hours 10 minutes ago En Égypte, ENGIE va construire et exploiter son plus grand parc éolien terrestre au monde